School of Chemistry and Molecular Biosciences (SCMB), The University of Queensland, St. Lucia, 4072 QLD Australia.
Drug Deliv Transl Res. 2013 Feb;3(1):100-9. doi: 10.1007/s13346-012-0085-z. Epub 2012 Jul 12.
The vast majority of human pathogens colonize and invade at the mucosal surfaces. Preventing infection at these sites via mucosally active vaccines is a promising and rational approach for vaccine development. However, it is only recently that the stimulation of local immunity at the mucosal surfaces has become a primary objective in addition to inducing systemic immunity. This review describes vaccine formulations designed for mucosal delivery to the nasal-associated lymphoid tissue, via intranasal administration. The association of antigens with mucosal adjuvants and delivery systems is emphasised.
绝大多数人类病原体在黏膜表面定植和入侵。通过黏膜活性疫苗在这些部位预防感染是疫苗开发很有前途和合理的方法。然而，直到最近，刺激黏膜表面的局部免疫除了诱导全身免疫外，也成为了一个主要目标。本综述描述了通过鼻腔内给药设计用于鼻腔相关淋巴组织黏膜传递的疫苗制剂。强调了抗原与黏膜佐剂和传递系统的结合。
